This article is more than 5 years old. Information may no longer be current.

LumiThera LT-300 granted CE mark for treating dry AMD

Issue: June 2018

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The European Union has granted a CE mark for the LT-300 light delivery system, a treatment device for dry age-related macular degeneration, LumiThera announced in a press release.

“The CE mark allows LumiThera to begin commercialization throughout the 28 EU member states and coincides with the initiation of the LIGHTSITE II clinical study in select European sites in the upcoming months,” Clark Tedford, PhD, LumiThera president and CEO, said in the release. “We are excited to be able to offer a safe and effective early-stage clinical intervention for patients with dry AMD.”

The LT-300 device uses photobiomodulation, which involves noninvasive light-emitting diodes for the treatment of ocular diseases.